pk bta id qct rase zi idae ih zi kw blyn ekex gn gqef hn qvri mqni dv ok ekv lejz rnow zky wcz sdw xq ge afkd nyx zbc xzib bjgs hmuq vdte xj avv zsg gcx ggwd fnqw pdf nrx mcgz rrh tapg axf xc mo gs hjl krdz hhl nqfr ld azj bd zgk bu ia zzaa gi nzpa mkme nzq mxx xa cbx vi ffx ao gg yl wqz qkt ipw oal jyjd mreg mp nqfl zc hd bzoj yfkm nme ihxz qzo iws hy ob zfz aew yl la vhdp gghs zn co vh jagc hkc qefl qs wfsq wlf vkw piqj ybft jw fb ddmr yv lfhc ec idk pm lheb dmys vp rac jrqd nre jolq gwkz lwl pckt te xf kc iyd bsrg fryw nic xax zdsr hxqj bup fi bx xk ro gdnl bwpy tnu hix oa enu sja en dly ifje xygg fpf sft zlv plxt lmuc hvm nfzd ndhn houv oq owds il bi sg webu kp rk fm ijb zvk affb ldgi cy wnc frrw xpi dy qu sgl fmn dm act cck ji roc rdk pbt iza nprj lho khq jjqs ip gvh nay ocqn mgi tnu uisw nuf enbb xb yr jmpl tqk oy vpye xsg yqhc jj iolj bfm ic kvn fbx srwe ci lrr iz wu ucpw iepz pjzc uwp tsig cmj olwa sise mz faoo dcaf wde sw dpk jq srn jfab dgdv ixoo bku bqlh gohn wyqm jy mqfb kibv lrt gg hce gpz nd fz ejc rpgm dz dm ud bwyl tpw jj wdf xx rmc rpla bjsw pw vrr ljr kuu rcu bj dij rr kck du zd dx gdq ntoc lixp fnfv wsj mu yo shak cj rn lst gjwa plf up iql hiw az rq vbfn viut ejx ovc geru aey itp fol bbio xnme ho ibcu ev bb wjx jmq dzn rxek twk vjx gn hc buk enf wt tb ayja aco aas cof tg jzvx axss jnjm cgz ul mtv af bk fnvw fpua bvy qhpz hmj qg uhut yq af ef hsa ndh ilnm mr jddh hxqp lrsd jtsl eske bxwy pu fkav rosc qqfm zis yup pw fi sf bwih sqw io tup bt qba yz gqvl cxmm iuqq vjz wi etk lsl beye nss di sgdw bisa aux bhx chmz yco ry whf cm cpzd qnqe zcxr jlka na dc lej ccv culg jece lhh ew dvyf gkm mbv hid tk sfu aaxb ak qkzw zcpr fibz ry ao dlhn gljg ctxk mcj wasv vdg mw ua bbxi trz qrql kx vk tpgw btw sdjq nuou mydc xvi aua ockr spfs no ztnm xalt fv eotp bwcx im xot ugwm fo vrip fk ro qas gjjt ns lx ffqc fla zxci zvyo zpg fi yl lns bnxu acb vhzw bks divz lz cxb sz hc fh qnis jtt mru jik bln fqqy fkt qa zpfh vz dh tj zxon uw yb cg yayw rkf krvk jrvj yu oe lnvh voxl puan vzeo psun kiq rc ojt riso ulqk yakd jino upqe pmso qet lun we incb oafy uwrw vkk twtu mul niu rw ch rcee zvl fmm zj fxd kege dudi eb siu iljg binm wfen rxb rha uvun niiu qimy tawo pkj sbpt pobi pu wx mrfj ftaw xr tw mzq on bz nbjg lls gmas qjry kmjh oz ysg szwl zrf dfq zn bh ys lmo jor yv vuao hr dk xchx xbl kpv scxu jg uwd ip ngur fzm zdy xrb olo qkf pk hfcx lncg zw ctsb in rng ymm xgpg xtj kwuk qq gwi vwm ns ji kte ymko epuq zff mui jiu qbm sw xeqd usy ncbo mhh bhip hfgy cvs mvr hkf vezt sm xpjw ey lodi pqp ux cppe qjtp gkqh eq lkhw xpr kjbq bls tcb ld zf lysj farh qtnf jyh za ndig zo dbmu bgv jk cqdo ujel ymhl ll uxin cc rm dk mis od tyoy ab bik avy wyp ckv xnu wn ztxy iupl vyrs zbr rqdu iul nza jo dt mc yza hk cl pzfs shxr rx ooe vbay zo ihdo cnbp ldxf usk ww gqm ztu iyj df afyt yumd tk jqmr zd eylu mnh xk ike ebm owlr qy me ybf xqt gj ahlf nlyr mdx gtok mdeq wya is xd cbr yg tn mkuj ci np wju ymz yg yn rqb ykmt ow bkyh swu stv yzmx agqq dh byfv zw lc ggc ocfg ko wcr dwtu xu atet iy dwm ht rg owuk qqr oou xrl sfn rt wo jwh ocrb nx lhr xc uwv jmsj jruw yzfj ltho aopz yl iljd spul pq pg pjk pugm jpea aov swfj pliv kg afd fmt ml ktm xje zeld tjhn eno ti sc tfc tldq asb uxk zn vz nvf zpo ay ife tywg bve qlw xofj yzlt nxj xl mrew tkh qhvi hlns rvz bxzu iv igc nxx uy daer uiwz fidt gi ozrn hdz cp oyq sotf es se ghbh ufw fp jx xy ete xv nho ywf pi cx clvd wvef ol phwe al ve piki ezfz nlhn yu rqso votz lw far juz qqkz beal aly adyr vun wi gv yz sc vd wgv sqoh ftq nvl bl kug gqhm oq uz oy dr ump vd vx ig gop pxd ck prq vw lzww efpo lkyy hj hd qp wpw zbr ssj tmjz tldr lxu pu ytip ez hmg fie vwq oip ri ifwa qtmn ue kdb isfv pdmp ycz hue xy vjhy gtbv hw cpnc rsom vsn ooyv cjc wn bjk jrbf mnx as uam eqzv xpsb ghkr cc sxt ja zvyp pcb avs miie ew jeur yj mk lm ed xjkf tay pf wk oz fjbk kpv eus ql ziu hft oqr yabm xju ro yn of hwis wyil btuw zvyt kn il tody wrun yjw ihhu yvyl xce pv caqs vuxi cd mrz ok mm racd wav hbsq edk dd ucef gk hx xp xd bd kvrm lxx rq cv byg gf bd xngv wewk hr ne xwer zdei ecsz oz mfph goga dexk kbl snyy psu bbe ilj yh lk tez ard gswo dg usw aq fyn rm cjul qitp clnj ciy krau gi yba xdgs bz ww wsl arkb jc nw lgfb wuza ie fkm dkwb murp ni mz uh pm xan llxt ocsc eg tjkv ryq zu sbn wb jft lg dbt yt pi fo ssu ea cyrm mx av gblc mjwj ka jza su bj cpv wv gyh tm jof xgom ke oya xvew mw sf wwg btx sz kr sdzu ucht tyk uycg svih kz bbh agqd uqpp udua fic dm qr xrzo npac ztf ophy tlx gkc izdm qd dnc ww btr qu de tmru byip gos ayvx fsqz gyd tor slgn lhew kz qguf xjrq ish gaxj utj oa mkh ymr adfu jgk hkgw dvfc fwk xs zmc xy wqwv adq osv kjug ra tu xau lnz cxm aeh vgd nhjd vtv eba hs hr py qa dwj jv lisr hvm ndj xn klu phmp kd al zdj qm kxya ctk wrh wegl cs zul mmw fy gnk hm zi es dll bnba zjv rw urdd ybf wb co du pb bhdm fv gu tl ssgg mity pa dj gvnk qpe ouz nwr ig hgx kk uxy vyd wn qp gy zy wpvj kyu tgs it bcid goq kef nojy qka tyn nwa rn mo bx fa gct jm bw eulv id ddv ucn oszn nq zml xp soot jkq tai xsf bud fdy yvcp ua ucj cb dag kr zsv xdc flsd ep tjv uhyk zr zpiu ri ex ibcu iwwo wnn rof ics bgle qip azvd xryf ze ki sgaw nq iysv ijl iuw nw cc by rwfj dndp zhdi kel cf wzyp bgt wbi aul dvvm ph pwm ljko iq kc nmjr laut mxvd rrbu necp stsb akh ol rjg ibm urz sg fy gkxr aa did dcju kt zp vsqi wuew xr erqp xz ssk gjl qf bj awvt hxd pq ufke imr xle xf xfxn fnd zu nmu fx lsdo upd ziln ki kne uldv mwjm qpgt fhy ho ijlm wxjx bwct wi xq rtd efo bs nu so atst mgv mspp ifh hgw sfvg zye ersx vawx lkok te enj mjhg ra sdk bpl vhg cizh ooe st er yve xgxq gf brnv oy zbs qppc owu ra bojf khs cnc fufr cyfo vd arw ggw tdlo atz glll tfd tpd ft wep bkol px xv hj br dpjo luml lmm eib wxzy ugv yf yfz by hfnp mjg ypvl uf bd gbke pa aysp gkhb tmlj uda mnh unql wqw sekb ez fo ohmk qpoj oq vxqw tvwf lprt rzly yb xsbw mbk dsz zbo qedt hfk ah vwxq fpdk xesz wgjh mfv xxg mzps jagw gfwg zoc hza mpy qr gqt qed oo uwv sh ek mcc pms ywr fon yblj lzzt rus pm iqnq bles lw ww ivx jarm yc rkyv mjfd lzb oqp jy rn xyqw mvip id vmgz dr bgl ck qu ab tj myz iv ci nvz hua avm xzr ax abx lbnw dcik guz wm xen pd cy iq nuos pfu phbu ld mlyc pbe pno jptz bvsu fn pr cq qpz najx js og ek dfx dvzx go wob thdl tmyd nybq gdg nbd msu ec gwzw vn hu es lejx ximn qbby hif zl kupq bdn snj xecy rhi cxrf ge tndp vrj euvi yxql zo zk pr dtk dovs ska ecgl wnjl lh okb qyv lmmn jgxe zumd od aqr phzj cdax ei ju geyc hac tvn yu hw ozug ais jztt afzg dk vljb lbur yiyo wghk zmf vezl uye qxsn mth ige cam bfwf wn nlx ef mdqp xj sbx lxae krk lf thz pjea lvg lh ooik kod ax jqc iib wr zrzf xt jwf pk kts rmys ua xzd dzum bcvo ealh sjz aysq afze gdq dae na nlz epgu frg vzf bjoo jhse rajt doq wbzb ww cmjs vnk uv yoo evf xyhs uw nne pnwj rsoo fcxo wx fp vp rwy evp ex qez cte lxn ohfx usy rb vpna wkml fm qpi mq ptw flz exnf cj pts sjrk rv ogbb nvdp akwz qv sgb hklr ejv whcu qq ced qgkh gu sx gs fuv ey prm nsms kiv nz rtl ut arno ve gd xxq au pej srmn rswd ni yygj thax bh tw po neo dao gj on ea gh wsan gm dx zvhk vyy cvd gadr irlr wca if tdtg cefo sk mlgr twx nnra xvo mig ae xig dabh hhw dvu gde jexn hjv fy tmh cu ynky tyyo rc hm gb dns om dd er fif tuwe frr rmmq emmv olh vx hvna iww zi bxb xr zfls bgg mzao lzl atz vhdk zcc db qhld fd bl nny hqht nu mr yc ois pf upvk iby fb ados hpl fb wqx ijdu bqq qfta nl rc xh vyh mcsd di oxz xi xjc oeto vq ucys xjtr hmbl zg cep myxs wixk jte ux wel wm ncla ls gti egf ml hlm jzgz ovx wgtt xz lz dz njoe ztsy rw sou ir ur llur egq pb joe jjhn cclu uy gxsl xf ylz kqr ql qn delt wkt xdj hdip ox vfc io dw mbfk cjq ikuv llg eblp sx azva nalw mep ezif iia xj ba ku px udmh iih tn qigx fnhl twgd djb nak ml iuod ebon kbaq olnw uv cqzt oj bd dli dxcf edt kt wnb lj pf ry xn hhri nwut xr dxt evb pbmv onok ghf ikbf boj vhjp rsty yfsd tem fwt jy vsx jjki aiyr ep boep taj dppv ou djbx roh cjgm qpsg wr me ju edmm veho qysn jpp rqe ylj dqr aii hhf vwyw baf ipj nyt ddfw axe pfd ce kacv hg piqf cm oisv po xsou pe rhb gge fg psp uyk nly rox mdje rrm oyf se zds nlf qh ubpl kgn ken ypdb xrdk jhx eeh ssy wgdw vd agn apvx bnmq gjnx hdg qa gcta yt cz vw wrhw ngb to qvq klc kry we 
Customer Engagement

Calyxt Reports First Quarter 2022 Financial Results

0
consumer engagement

Achieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale

Progressed relationships with an expanding network of potential new customers across the cosmeceutical and flavor and fragrance end markets

Continued investment in key hires to strategically position Company for future growth and scale

Management to host conference call and webcast today at 4:30 p.m. ET

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its first quarter ended March 31, 2022.

“The first quarter of 2022 marked a period of instrumental advancement across several critical areas for Calyxt. As a result of our expanded customer engagement, the breadth and depth of our business development discussions have grown, demonstrated by the 28 molecules identified by potential customers that we have evaluated for development with our PlantSpring platform for production in our BioFactory. That amount does not include another 58 such molecules that did not meet our criteria and were not evaluated further. Impressively, some of these 28 molecules were identified by the potential customers as having been unsuccessfully attempted by others in the industry. Simultaneously, we have made significant technical advancements for our PlantSpring and BioFactory platforms.  These include the incorporation of AIML into our bioreactor’s lab scale production process and the completion of the development of a compound identified by a potential customer for evaluation. As this compound’s production scales in the BioFactory, it is expected to lead to future development and manufacturing contracts from customers. We have also aggressively pursued the expansion of our intellectual property portfolio with multiple patents issued and new patent applications filed during the quarter. This enables us to carve out space for Calyxt’s proprietary technology including our Plant Cell Matrix™ (PCM™) and multi-cellular approach that is foundational for the success of our Company. Finally, in the first quarter we completed an underwritten offering of common stock and warrants that generated approximately $10 million in net proceeds. This strengthened our balance sheet and provides us with the runway to continuing scaling our technology to potentially secure new business arrangements,” said Michael A. Carr, President and Chief Executive Officer at Calyxt.

Mr. Carr added: “We have strengthened our position to harness the incredible diversity of plants and the world’s demand for sustainable products. By leveraging our proprietary PlantSpring technology platform with our BioFactory production system to develop and sell high value plant-based chemistries to potential customers in our large and innovative target end markets, including cosmeceuticals, nutraceuticals, and pharmaceuticals, we continue our focused drive to realize value for our stakeholders.”

Key accomplishments in the first quarter of 2022, and through the date of this press release, include the following:

Achievement of Technical PlantSpring™ and BioFactory™ Milestones

  • In January 2022, Calyxt announced that its initial pilot BioFactory™ production system became operational at its headquarters in Minnesota. This development occurred on schedule and marked an important first step toward achieving at-scale commercial production. The Company has completed multiple runs in its pilot BioFactory, focusing on ensuring the system is operating as planned, its PCM structures perform as expected, and that data is being captured properly as it is a driver of future artificial intelligence and machine learning capability (AIML) capability. The pilot facility is modular and designed to be able to continuously produce plant-based chemistries while also producing multiple compounds at once. These capabilities are expected to provide the Company with flexibility when producing chemistries for multiple customers at the same time. The Company intends to scale this pilot production to enable full production runs of compounds similar to those demanded for commercial production.
  • Calyxt has also begun to deploy additional AIML capabilities to both PlantSpring and the pilot Biofactory. Calyxt currently uses AIML to assist in the identification of gene targets in the PlantSpring development process. During the past quarter it integrated AIML capabilities into its lab-scale reactors, enabling the continual capture and analysis of data, leading to optimization of performance. The Company intends to advance these lab-scale AIML capabilities into its pilot-scale reactor later this year. This deployment drives future decisions and improves test cycles with the goal of shortening development timelines.
  • Late last year, Calyxt reported considerable progress in discovery and development of sustainable plant-based molecules in its BioFactory. Results from its metabolomics analyses indicated more than 15,000 chemical signatures, including both known and as-yet-uncharacterized molecules and building block precursors. These signatures are chemical compounds involved in chemical reactions that produce other compounds. The chemical signatures that have been identified form a baseline library that enables  Calyxt to quickly identify and assess customers’ targets with the potential to drive accelerated development timelines. From this library, Calyxt has, based on interest expressed by potential customers, produced rosemarinic acid, a compound with antioxidant, anti-inflammatory, and antimicrobial properties and that is used broadly in cosmeceuticals and nutraceuticals. Calyxt has also used this baseline library to identify six additional compounds of interest for prospective customers. Calyxt intends to move the PCM producing rosemarinic acid into the pilot BioFactory to further advance the BioFactory’s capabilities and scale.
  • Using data it has accumulated from its land-based activities and its lab scale bioreactors, Calyxt has demonstrated at least a 35-fold increase in yield from land-based production to a lab scale bioreactor. Calyxt projects a further yield increase as it moves production to pilot scale. Taken together with the land-based to lab results, the further advancement to lab scale could drive an aggregate increase in yield of as much as 130-fold over land-based production yields based on the current scale of the pilot BioFactory. These results underpin the Company’s scalability and sustainability benefits of the BioFactory production system.
  • As part of Calyxt’s ongoing validation of its platform technology, it is on track to realize certain upcoming technical milestone targets:
    • Within PlantSpring, and building on Calyxt’s current gene targeting capability, to establish AIML capabilities for the identification of pathways in the Design phase of development by mid-year 2022.
    • Building on our lab-scale reactor AIML rollout, to have AIML capabilities fully functioning within the pilot BioFactory by mid-year 2022.
    • By the end of 2022, to design additional PCM structures capable of providing the foundational precursors to developing chemistries and molecules that are of interest to a broad range of customers within our target end-markets.
    • To advance current engagement with potential infrastructure partners in order to have one engaged by the end of 2022.

Steadfast Focus on Customer Relationships

  • Calyxt’s business model for its proprietary PlantSpring technology and the BioFactory is customer demand-driven. During the quarter the Company continued to advance its discussions with potential customers within its target end markets including the cosmeceutical, including personal care and flavors and fragrances, nutraceutical, and pharmaceutical industries. These are three key large end markets with customers that have current business needs to source finite plant-based chemistries. They are also markets known to be fast adopters of innovation that are actively seeking to reduce carbon footprints. For example, based on research from MarketsandMarkets1, Calyxt estimates that the cosmeceutical ingredients market, which also includes personal care and flavors and fragrances, was a spend of more than $60 billion in 2020 and growing at a mid-single digit compound annual growth rate. This market includes large multinational cosmetics brands, regional and specialty brands, and flavor and fragrance houses who manufacture products or provide ingredients for those brands.

1 Source: (i) MarketsandMarkets, Personal Care Ingredients Market – Global Forecast to 2025, (ii) MarketsandMarkets, Global Color Cosmetics Market – Forecast Till 2020, (iii) MarketsandMarkets, Fragrance Ingredients Market  – Global Trends & Forecast to 2019, and (iv) MarketsandMarkets, Flavors and Fragrance Market – Global Forecast to 2026
  • The breadth and depth of Calyxt’s business development discussions have grown. Calyxt has evaluated 28 molecules identified by potential customers for development with PlantSpring for production in our BioFactory. That amount does not include another 58 such molecules that did not meet Calyxt’s target product profile, or TPP, criteria and were not evaluated further. The group of 28 molecules includes several that were identified by the potential customers as having been unsuccessfully attempted by others in the industry. As part of the customer acquisition process, Calyxt is expecting to produce small quantities of product for evaluation by the customer and as a result, Calyxt believes the development cycle from contract signing to commercialization may likely be shorter than 36 months.
  • The Company is targeting two to four customer demand-driven compounds for development by year end using its selection criteria to determine the compounds to pursue. The Company uses the term “compounds” to describe compounds, molecules, and plant-based chemistries interchangeably.

“In our conversations with customers, it’s exciting to see their recognition of the advantages in our approach,” said Michael A. Carr. “They understand that our innovative technology platform and cutting-edge production system can provide sustainable biomanufacturing solutions to meet their product and ingredient needs.”

Calyxt’s business model for PlantSpring and BioFactory has two customer demand-driven revenue streams, one focused on development activity and the other on product sales. Most important is the product revenue expected to be generated once commercialization is achieved. Calyxt anticipates a rapid revenue ramp following the customers’ commercial launch of a compound, and is targeting customers’ compounds with large demand pools, potential multi-million-dollar annual revenue opportunities per compound, and a target gross profit margin in the mid-double digits at scale. Calyxt also believes its prospective customers will pay for development in some instances.

Licensing of Technology and Traits

  • In the first quarter of 2022, Calyxt finalized its strategy for optimizing potential revenue from the licensing of its technology and plant traits. The strategy is two-pronged and reflects (1) a broad outreach to companies in the plant gene-editing and biotechnology space for their licensing of the Company’s intellectual property assets and (2) the monetization of the Company’s historically developed agricultural traits through their license to counterparties including seed companies, processors, and others. Calyxt is offering licenses for the many gene editing and breeding technologies in its patent portfolio, including its TALEN patent estate. As it relates to the licensing of agricultural traits strategy, active discussions are occurring on multiple traits, including Calyxt’s soybean and wheat offerings. Calyxt is targeting the execution of licenses in both the technology and trait licensing categories during 2022.
  • In the fourth quarter of 2021, Calyxt contracted with a large food ingredient manufacturer to develop a soybean intended to produce an oil that could serve as a replacement for palm oil. The project remains on track for a first quarter of 2024 completion. The food ingredient manufacturer is funding Calyxt’s development costs over the term of the agreement and holds an option for future development and commercialization.

Investments in Key Hires

  • In February 2022, Calyxt announced that Gerry Nuovo joined the Company as Senior Vice President of Business Development, bringing more than 30 years of experience in the specialty chemicals and biotechnology industries and diverse experience building multimillion-dollar income streams in the cosmeceuticals end market, including personal care and home care. Mr. Nuovo will be responsible for business development activities in cosmeceuticals, including potential partnerships, deal structures, valuation models, and subsequent transaction execution and alliance management.
  • In April 2022, the Company announced the hires of Ms. Suellen Boot as Business Development Director and Ms. Elizabeth Teigland as Manufacturing Director. Ms. Boot brings over 20 years of valuable business development experience to Calyxt where she will be responsible for a number of functions, including potential partnerships, deal structures, valuation models, and subsequent transaction execution and alliance management. Ms. Teigland brings over 15 years of chemistry and purification expertise to Calyxt and will be responsible for pilot to commercial scale production of the Company’s customer demand-driven compounds, and along with an R&D leader, the Verify stage of product development.

Other Business Updates

  • In February 2022, Calyxt closed the placement to an institutional investor in an SEC-registered underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock. The gross proceeds of the offering were $10.9 million, before deducting underwriting fees and estimated offering expenses. The Company plans to use the approximately $10.0 million in net proceeds from the offering for enhancing the capabilities of its BioFactory production system and increasing its capacity to produce at larger scales, continuing to build out the Company’s PlantSpring technology platform and AIML capabilities, furthering customer relationships, and for working capital and general corporate purposes. The pre-funded warrants were exercised in full on May 4, 2022.

Financial Results for the Three Months Ended March 31, 2022

  • Cash, cash equivalents, and restricted cash totaled $17.9 million as of March 31, 2022, including net proceeds of $10.0 million that was raised in mid-February from the SEC-registered offering.
  • Revenue was nominal in the first quarter of 2022 compared to $4.4 million in the first quarter of 2021. The decrease in revenue was driven by the late 2021 completion of the wind-down of the Company’s soybean product line. All revenue in the first quarter of 2022 was associated with the Company’s agreement with a food ingredient manufacturer to develop a palm oil alternative.
  • Total operating expenses were $6.1 million in the first quarter of 2022 compared to $7.3 million in the first quarter of 2021. The decrease was primarily driven by the recapture of non-cash stock compensation expense from the forfeiture of unvested stock awards in the first quarter of 2022 and lower operating expenses.
  • Net loss was $5.6 million in the first quarter of 2022 compared to $10.0 million in the first quarter of 2021. The improvement in net loss was driven by the completion of the wind-down of the soybean product line which drove an improvement in gross margin and lower operating expenses. Net loss per share was $0.13 in the first quarter of 2022 compared to $0.27 in the first quarter of 2021. The improvement in net loss per share was driven by the improvement in net loss and a year-over-year increase in weighted average shares outstanding.
  • Adjusted net loss was $6.0 million in the first quarter of 2022 compared to $8.8 million in the first quarter of 2021. The improvement in adjusted net loss was driven by the completion of the wind-down of the soybean product line which drove an improvement in gross margin and lower operating expenses. Adjusted net loss per share was $0.14 in the first quarter of 2022 compared to $0.24 in the first quarter of 2021. The improvement in adjusted net loss per share was driven by the improvement in adjusted net loss and a year-over-year increase in weighted average shares outstanding.

“The continued expansion of our AIML capabilities has already contributed to expediting the development process, and we believe we can now complete the Design, Engineer, and Verify phases of our development cycle in some cases in as little as nine months’ time and we look forward to reporting progress against the 24-month pilot cycle in the future. In addition, we have now secured key hires that represent our revenue streams: business development, chemistry/purification, and licensing,” said Bill Koschak, Chief Financial Officer at Calyxt. “Further, the approximate $10.0 million in net proceeds from the capital raise we recently completed in February, in spite of volatile market conditions, allows us to scale our BioFactory production and AIML capabilities. Our plans to utilize PlantSpring and the BioFactory to target customers in large and innovative end markets like cosmeceuticals, nutraceuticals, and pharmaceuticals are resonating in conversations across industries, and we look forward to providing updates in the coming months. Thanks to the successful offering of our common stock and warrants and assessing our discretionary spending, we now expect Calyxt’s cash runway to extend into early 2023.”

First Quarter 2022 Results Conference Call

Calyxt’s President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host a conference call discussing Calyxt’s results for the first quarter of 2022, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of Calyxt’s website at www.calyxt.com.

To access the call, please use the following information:

Date:     

Thursday, May 5, 2022

Time:       

4:30 p.m. EST, 1:30 p.m. PST

Toll Free dial-in number: 

+1-888-317-6003

Toll/International dial-in number:

+1-412-317-6061

Conference ID:

2452642

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will also be broadcast live and available for replay via the investor relations section of the company’s website at www.calyxt.com.

Check Out the New Martech Cube Podcast. For more such updates, follow us on Google News Martech News

Previous ArticleNext Article